Titre:
  • Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: A randomised, controlled, phase 3 trial
Auteur:Goss, Paul E; Smith, Ian; O'Shaughnessy, Joyce; Ejlertsen, Bent; Kaufmann, Manfred; Boyle, Frances; Buzdar, Aman; Fumoleau, Pierre; Gradishar, William; Martin, Miguel; Moy, Beverly; Piccart-Gebhart, Martine; Pritchard, Kathleen; Lindquist, Deborah; Chavarri-Guerra, Yanin; Aktan, Gursel; Rappold, Erica; Williams, Lisa L.S.; Finkelstein, Dianne D.M.
Informations sur la publication:Lancet oncology, 14, 1, page (88-96)
Statut de publication:Publié, 2013-01
Sujet CREF:Cancérologie
MeSH keywords:Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized -- administration & dosage
Breast Neoplasms -- drug therapy -- pathology
Chemotherapy, Adjuvant -- adverse effects
Disease-Free Survival
Drug-Related Side Effects and Adverse Reactions -- chemically induced -- classification
Female
Humans
Lymph Nodes -- pathology
Middle Aged
Neoplasm Staging
Quinazolines -- administration & dosage -- adverse effects
Receptor, ErbB-2 -- metabolism
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1470-2045
info:doi/10.1016/S1470-2045(12)70508-9
info:pii/S1470204512705089
info:scp/84871712684
info:pmid/23234763